American College of Clinical Pharmacy
      Search      Cart
         

2024 ACCP/ASHP BCPPS Clinical Sessions


Member Price:
$155.00
Nonmember Price:
$260.00

 

ASHP members, please visit www.rxcertifications.org to receive member pricing.

The 2024 ACCP/ASHP BCPPS Clinical Sessions are part of the professional development programs for recertification of the Board-Certified Pediatric Pharmacy Specialist® (BCPPS), and/or the Board-Certified Critical Care Pharmacist® (BCCCP), and/or the Board-Certified Emergency Medicine Pharmacist® (BCEMP) approved by the Board of Pharmacy Specialties (BPS) and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

Release Date: December 18, 2024
BCPPS Deadline: December 16, 2025
ACPE Deadline: October 13, 2027

Technical Requirements:

Contents

BCPPS Clinical Session
Leveraging Biologics: Treatment Advances in the Management of Childhood-Onset Systemic Lupus Erythematosus

Treatment of childhood-onset systemic lupus erythematosus (cSLE) has been limited to traditional immunomodulators until the recent introduction of biologic therapy. Knowledge of these agents and their role in treatment is necessary for the pediatric pharmacist to develop an effective and safe therapeutic regimen and monitoring plan. This session will focus on the role of biologic therapy in the management of cSLE using interactive patient cases and in-depth evaluation of the current literature in order to equip the pediatric pharmacist with the necessary knowledge and tools to integrate into clinical practice.

BCPPS/BCCCP Clinical Session
New and Pipeline Antibiotics for Gram-Negative Bacterial Infections

Antibiotic resistance has increasingly become more common in clinical practice, with multidrug-resistant (MDR) gram-negative bacteria contributing to prolonged hospital stays, increased healthcare costs, and high mortality rates among adult and pediatric populations. Using complex and challenging real-world cases, this session will present clinical evidence supporting the newer and pipeline antibiotics to treat MDR gram-negative bacterial infections and evaluate recent literature and updates in gram-negative bacterial infection management. Attendees will learn to identify patient-specific risk factors for MDR gram-negative bacterial infections, interpret resistance patterns accurately, and understand the place in therapy of the newer antibiotics to select the most appropriate antibiotic and improve patient outcomes.

BCPPS/BCCCP/BCEMP Clinical Session
Nick-NAC APAP Whack

Acetaminophen toxicity demands emergency medical treatment; left untreated, significant morbidity or death can result. Although different dosing strategies for N-acetylcysteine (NAC) have been proposed, no singular dosing strategy has been identified as superior. While recent guidelines have been released, there are many unanswered questions regarding preferred NAC dosing regimens and the use of adjunctive treatment agents. Through the use of patient cases, this interactive session will discuss real-world supratherapeutic acetaminophen ingestions, management of the pediatric patient with acetaminophen toxicity, and implementation of adjunctive agents outside of NAC. In addition, patient safety and monitoring of these dosing regimens will be reviewed. Evidence-based recommendations on the use of extracorporeal treatments for acetaminophen toxicity will also be reviewed.

BCPPS Clinical Session
Leveraging Biologics: Treatment Advances in the Management of Childhood-Onset Systemic Lupus Erythematosus

Faculty

Ingrid Pan, Pharm.D., BCPPS

Ambulatory Rheumatology Pharmacist
Children’s Hospital of Colorado
Aurora, Colorado

BCPPS/BCCCP Clinical Session
New and Pipeline Antibiotics for Gram-Negative Bacterial Infections

Faculty

Kalen B. Manasco, Pharm.D., FCCP, FPPA, BCPPS, BCPS

Clinical Professor and Division Head
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy
Gainesville, Florida

Trang D. Trinh, Pharm.D., MPH, BCIDP, BCPS

Associate Professor of Clinical Pharmacy
University of California, San Francisco
School of Pharmacy
San Francisco, California

BCPPS/BCCCP/BCEMP Clinical Session
Nick-NAC APAP Whack

Faculty

Megan E. Musselman, Pharm.D., FCCP, FASHP, BCCCP, BCEMP, BCPS

Clinical Pharmacy Specialist, Emergency Medicine/Critical Care
North Kansas City Hospital
Kansas City, Missouri

David E. Zimmerman, Pharm.D., FASHP, BCCCP, BCEMP

Associate Professor of Pharmacy
Duquesne University School of Pharmacy;
Emergency Medicine Pharmacist
University of Pittsburgh Medical Center-Mercy Hospital
Pittsburgh, Pennsylvania

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of of BCPPS.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.

Target Audience: These recertification activities are intended for the Board-Certified Pediatric Pharmacy Specialist® (BCPPS) and/or the Board-Certified Critical Care Pharmacist® (BCCCP) and/or the Board-Certified Emergency Medicine Pharmacist® (BCEMP) and those interested in childhood-onset systemic lupus erythematosus, antibiotics for gram-negative bacterial infections, and Acetaminophen toxicity.

Contents

BCPPS Clinical Session
Leveraging Biologics: Treatment Advances in the Management of Childhood-Onset Systemic Lupus Erythematosus

Activity Number: 0217-9999-24-069-H01-P
Contact Hour(s): 1.00
Activity Type: Application Based

Learning Objectives

Leveraging Biologics: Treatment Advances in the Management of Childhood-Onset Systemic Lupus Erythematosus

  1. Examine current non-biologic standards of care for childhood-onset systemic lupus erythematosus.
  2. Evaluate current literature for the role and integration of biologic therapy in the management of childhood-onset systemic lupus erythematosus.
  3. Develop strategies to manage biologic therapy for hospital and health-system formularies.

BCPPS/BCCCP Clinical Session
New and Pipeline Antibiotics for Gram-Negative Bacterial Infections

Activity Number: 0204-9999-24-254-H01-P
Contact Hour(s): 1.50
Activity Type: Application Based

Learning Objectives

New and Pipeline Antibiotics for Gram-Negative Bacterial Infections

  1. Compare the spectrum of activity, pharmacokinetics, and pharmacodynamic properties of newly approved antibiotics for the treatment of difficult-to-treat gram-negative bacterial infections in adult and pediatric populations.
  2. Interpret biomedical literature including study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to adult and pediatric patients with difficult-to-treat gram-negative bacterial infections.
  3. Given a description of an adult or pediatric patient with a difficult-to-treat gram-negative infection, design an antibiotic regimen that reflects the application of the best available evidence and current guidelines.

BCPPS/BCCCP/BCEMP Clinical Session
Nick-NAC APAP Whack

Activity Number: 0204-9999-24-278-H01-P
Contact Hour(s): 1.50
Activity Type: Application Based

Learning Objectives

Nick-NAC APAP Whack

  1. Evaluate current guideline recommendations for patients presenting with acetaminophen toxicity.
  2. Develop an effective treatment regimen for the management of a patient presenting with acetaminophen toxicity.
  3. Develop monitoring strategies for the different medications used to treat acetaminophen toxicity.
  4. Design an effective treatment plan for patients requiring adjunctive treatment options for acetaminophen toxicity.

Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.